Why the study?
Does riociguat improve exercise capacity and pulmonary vascular resistance in patients with chronic thromboembolic pulmonary hypertension?
Does riociguat improve exercise capacity and pulmonary vascular resistance in patients with chronic thromboembolic pulmonary hypertension?
Riociguat provides significant improvements in functional and hemodynamic surrogate markers for patients with chronic thromboembolic pulmonary hypertension.
Supports riociguat in CTEPH; strengthens low-certainty evidence with new randomized data.
Riociguat significantly improved exercise capacity and pulmonary vascular resistance in patients with chronic thromboembolic pulmonary hypertension. (Funded by Bayer HealthCare; CHEST-1 and CHEST-2 ClinicalTrials.gov numbers, NCT00855465 and NCT00910429, respectively.)
No takes yet. Share an insight, caveat, or question.
Ghofrani et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: